Company intelligence / Profile preview
Cardior Pharmaceuticals
Hannover, Lower Saxony, Germanycardior.de ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Cardior’s lead compound CDR132L, an antisense oligonucleotide targeting miR‑132, has shown a favorable safety profile and beneficial cardiac effects in a Phase Ib trial for chronic heart failure. It is currently being evaluated in the international Phase 2 HF‑REVERT study for post-MI patients with cardiac dysfunction. The company’s approach aims to halt and reverse detrimental cardiac remodeling after myocardial infarction—the first ncRNA-based therapy to enter clinical trials for heart disease[6].
> “CDR132L reverses cellular pathology, restoring normal heart muscle cells and overall heart function.” — Dr. Thomas Thum (CSO & Co-founder)[5]
Novo Nordisk acquired Cardior in March 2024 to accelerate late-stage development of CDR132L as a potentially transformative therapy for heart failure[3][10].- Therapeutic areas
- Cardiovascular
- Modalities
- Non-coding RNA therapeuticsantisense oligonucleotides[1][5][7]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Bristol Myers Squibb (investor/partner)[8]
Beyond the preview
Go deeper on Cardior Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cardior Pharmaceuticals.